核医学在乳腺癌前哨淋巴结活检术中的方法学研究现状

李蕾; 杨国仁; 李蕾; 杨国仁

doi:10.3760/cma.j.issn.1673-4114.2013.03.013

[1]

Cody HS 3rd. Sentinel lymph node biopsy. London:Martin Dunitz Ltd, 2002:20-43.

[2]

Nathanson SD, Anaya P, Karvelis KC, et al. Sentinel lymph node uptake of two different technetium-labeled radiocolloids. Ann Surg Oncol, 1997, 4(2):104-110. doi: 10.1007/BF02303791

[3]

刘峰, 王华, 施常备.前哨淋巴结显像剂的应用现状及发展.现代肿瘤医学, 2003, 11(4):314-315. doi: 10.3969/j.issn.1672-4992.2003.04.049

[4]

Harlow SP, Krag DN. Sentinel lymph node biopsy in breast cancer. Breast Dis, 2001, 12:43-45. doi: 10.3233/BD-2001-12106

[5]

Edreira MM, Colombo LL, Perez JH, et al. In vivo evaluation of three different 99mTc-labelled radiopharmaceuticals for sentinel lymph node identification. Nucl Med Commun, 2001, 22(5):499-504. doi: 10.1097/00006231-200105000-00006

[6]

Jakub JW, Cox CE, Pippas AW, et al. Controversial topics in breast lymphatic mapping. Semin Oncol, 2004, 31(3):324-332. doi: 10.1053/j.seminoncol.2004.03.014

[7]

杨国仁, 王永胜, 张鹏, 等. ⁹⁹Tc^m-SC显像联合蓝染法探测乳腺癌前哨淋巴结.中华核医学杂志, 2003, 23(3):136-138. doi: 10.3760/cma.j.issn.2095-2848.2003.03.002

[8]

Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood, 1994, 83(2):435-445. doi: 10.1182/blood.V83.2.435.435

[9]

王雪鹃, 杨志, 林保和, 等.前哨淋巴结显像剂⁹⁹Tc^m-IT-Rituximab的制备及其定位性能.中华核医学杂志, 2006, 26(4):226-230. doi: 10.3760/cma.j.issn.2095-2848.2006.04.010

[10]

Phillips WT, Klipper R, Goins B. Use of ^99mTc-labeled liposomes encapsulating blue dye for identification of sentinel lymph node. J Nucl Med, 2001, 42(3):446-451.

[11]

周敏, 章英剑, 程竞仪, 等.内乳前哨淋巴结⁹⁹Tc^m-硫胶体显像影响因素分析.中华核医学杂志, 2009, 29(1):8-11. doi: 10.3760/cma.j.issn.0253-9780.2009.01.004

[12]

Harlow SP, Krag DN, Julian TB, et al. Prerandomization Surgical Training for the National Surgical Adjuvant Breast and Bowel Project(NSABP) B-32 trial:a randomized phase Ⅲ clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer. Ann Surg, 2005, 241(1):48-54. doi: 10.1097/01.sla.0000149429.39656.94

[13]

Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer:the ALMANAC Trial. J Natl Cancer Inst, 2006, 98(9):599-609. doi: 10.1093/jnci/djj158

[14]

James TA, Edge SB. Sentinel lymph node in breast cancer. Curr Opin Obstet Gynecol, 2006, 18(1):53-58.

[15]

Nieweg OE, Estourgie SH, van Rijk MC, et al. Rationale for superficial injection techniques in lymphatic mapping in breast cancer patients. J Surg Oncol, 2004, 87(4):153-156. doi: 10.1002/jso.20108

[16]

Kinoshita T. Sentinel lymph node biopsy is feasible for breast cancer patients after neoadjuvant chemotherapy. Breast Cancer, 2007, 14(1):10-15.

[17]

Mudun A, Sanli Y, Ozmen V, et al. Comparison of different injection sites of radionuclide for sentinel lymph node detection in breast cancer:single institution experience. Clin Nucl Med, 2008, 33(4):262-267. doi: 10.1097/RLU.0b013e3181662fc7

[18]

Rodier JF, Velten M, Wilt M, et al. Prospective multicentric randomized study comparing periareolar and peritumoral injection of radiotracer and blue dye for the detection of sentinel lymph node in breast sparing procedures:FRANSENODE trial. J Clin Oncol, 2007, 25(24):3664-3669. doi: 10.1200/JCO.2006.08.4228

[19]

Noguchi M, Inokuchi M, Zen Y. Complement of peritumoral and subareolar injection in breast cancer sentinel lymph node biopsy. J Surg Oncol, 2009, 100(2):100-105. doi: 10.1002/jso.21308

[20]

杨余朋, 郑刚, 郑美珠, 等.乳腺癌前哨淋巴结解剖学定位及其临床意义的研究.中华肿瘤防治杂志, 2010, 17(14):1100-1103.

[21]

Lerman H, Metser U, Lievshitz G, et al. Lymphoscintigraphic sentinel node identification in patients with breast cancer:the role of SPECT-CT. Eur J Nucl Med Mol Imaging, 2006, 33(3):329-337. doi: 10.1007/s00259-005-1927-4

[22]

杨国仁, 张秀丽, 孙晓蓉, 等. FDG PET/CT联合⁹⁹Tc^m-SC前哨淋巴结显像诊断乳腺癌.中华核医学杂志, 2004, 24(5):312. doi: 10.3760/cma.j.issn.2095-2848.2004.05.023

[23]

Paredes P, Vidal-Sicart S, Zanón G, et al. Radioguided occult lesion localization in breast cancer using an intraoperative portable gamma camera:first results. Eur J Nucl Med Mol Imaging, 2008, 35(2):230-235. doi: 10.1007/s00259-007-0640-x

[24]

Jakub JW, Cox CE, Pippas AW, et al. Controversial topics in breast lymphatic mapping. Semin Oncol, 2004, 31(3):324-332. doi: 10.1053/j.seminoncol.2004.03.014

[25]

Torrenga H, Meijer S, Fabry H, et al. Sentinel node biopsy in breast cancer patients:triple technique as a routine procedure. Ann Surg Oncol, 2004, 11(3 Suppl):S231-235.

[26]

Uren RF, Howman-Giles R, Chung D, et al. Nuclear medicine aspects of melanoma and breast lymphatic mapping. Semin Oncol, 2004, 31(3):338-348. doi: 10.1053/j.seminoncol.2004.03.007

[27]

Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer:results from the NSABP B-32 randomised phase Ⅲ trial. Lancet Oncol, 2007, 8(10):881-888. doi: 10.1016/S1470-2045(07)70278-4

[28]

Dutta R, Kluftinger A, MacLeod M, et al. Revisiting the "10% rule"in breast cancer sentinel lymph node biopsy:an approach to minimize the number of sentinel lymph nodes removed. Am J Surg, 2012, 203(5):623- 627. doi: 10.1016/j.amjsurg.2012.01.010

[29]

McCarter MD, Yeung H, Fey J, et al. The breast cancer patient with multiple sentinel nodes:when to stop?. J Am Coll Surg, 2001, 192(6):692-697. doi: 10.1016/S1072-7515(01)00847-X

[30]

Low KS, Littlejohn DR. Optimal number of sentinel nodes after intradermal injection isotope and blue dye. ANZ J Surg, 2006, 76(6):472-475. doi: 10.1111/j.1445-2197.2006.03752.x

[31]

National Comprehensive Cancer Network. NCCN clinical practice guidelines in Oncology: breast cancer[EB/OL]. [2012-09-10].http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.